Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656511 · ClinicalTrials.gov registry record · Phase 4
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
A Phase 4 study of HIV, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 4
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT02656511 is a Phase 4 study of HIV that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 74 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02656511, a Phase 4 study of HIV, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify and provide immediate antiretroviral therapy to a cohort of HIV-infected individuals with very early HIV infection (estimated date of infection within the last 90 days). The primary aim of the study is to evaluate whether initiation of dolutegravir plus emtricitabine/tenofovir during acute/early HIV infection leads to protection of CD4+ T cells and other immune cells in the peripheral blood and lymphoid tissue from infection.
Conditions Studied
Interventions
- DRUG Dolutegravir
- DRUG Emtricitabine/Tenofovir
Study Locations (1)
California
- San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2015-12 |
| Est. Completion | 2028-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02656511
The ClinicalTrials.gov registry entry for NCT02656511 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Dolutegravir is the first listed.
NCT02656511 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02656511 about?
NCT02656511 is a clinical study titled "Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection". The purpose of this study is to identify and provide immediate antiretroviral therapy to a cohort of HIV-infected individuals with very early HIV infection (estimated date of infection within the last 90 days). The primary aim of the study is to evaluate whether initiation of dolutegravir plus emtri...
What is the current status of trial NCT02656511?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 74 participants. The study started on 2015-12. Estimated completion is 2028-05.
What conditions does trial NCT02656511 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT02656511?
The interventions under investigation include: Dolutegravir (DRUG), Emtricitabine/Tenofovir (DRUG).
Who is sponsoring clinical trial NCT02656511?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02656511 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
RECRUITING · Phase 4
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
RECRUITING · Phase 4
-
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.